breast-cancer-summit-2017-scientifictracks-abstracts

12 / 12

Page 36
Notes:
conferenceseries.com
Volume 2, Issue 2 (Suppl) Breast Can Curr Res
ISSN: 2572-4118 BCCR, an open access journal Breast Cancer Summit 2017
May 08-10, 2017
May 08-10, 2017 Singapore
4th World Congress on
Breast Cancer
Amplification and over-expression of MAP3K3 gene in human breast cancer promotes formation and
survival of breast cancer cells
Hong (Amy) Zhang
University of Texas at Austin, USA
Gene amplification in the 17q chromosomal region is observed frequently in breast cancers. An integrative bioinformatics analysis
nominated MAP3K3 gene, located in 17q23, as a potential therapeutic target in breast cancer. This gene encodes the mitogen-
activated protein kinase kinase kinase 3 (MEKK3), but has not yet been associated with cancer-causal genetic aberrations. We
found that MAP3K3 was amplified in approximately 8-20% of breast carcinomas, and that its over-expression was an independent
prognostic marker for poor outcome with respect to relapse-free and overall survival, especially among the estrogen receptor-positive
breast cancer patients. shRNA- mediated knockdown of MAP3K3 expression significantly inhibited cell proliferation and colony
formation of MAP3K3-amplified breast cancer cell lines MCF7 and MDA-MB361, and promoted breast cancer cell apoptosis induced
by TNFα, TRAIL, or a doxorubicin. In addition, ectopic expression of MAP3K3, in collaboration with Ras, induced colony formation
in both primary mouse embryonic fibroblasts and immortalized mammary epithelial cells (MCF-10A). Together, these results suggest
that MAP3K3 is a potential biomarker indicating poor prognosis, contributes to resistance to therapy, and is an oncogene in breast
carcinogenesis. Therefore, therapeutic targeting of MAP3K3 may be attractive in breast cancer patients with MAP3K3-amplified
breast cancer.
Biography
Amy Hong Zhang is currently an Associate Professor in the Department of Pathology and Translational Molecular Pathology in University of Texas-MD Anderson
Cancer Center in Houston, TX, specializing on breast cancer pathology. She is an American Board certified practicing Pathologist since 2003. She has expertise in
diagnosing breast cancers and the interpretation of the biomarkers relevant to breast cancers for patient care. She is also actively supervising research scientists
and trainees on translational and laboratory research, focusing on the characterization of tumor markers significant for breast tumorigenesis and the development
of small molecule inhibitors and potential novel molecular targets for breast cancer treatments in a different way of focusing.
Muthu K Shanmugam et al., Breast Can Curr Res 2017, 2:2(Suppl)